Research article · 8 Jul 2016
Research articlePublished 25 Apr 2022
Bioequivalence study of a new fixed-dose combination tablet containing irbesartan and hydrochlorothiazide in healthy volunteers
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background and objective: The combination antihypertensive therapy has shown greater blood pressure lowering potential as well as better adherence to the treatment. Therefore, a new generic fixed-dose combination containing irbesartan and hydrochlorothiazide was developed and rate and extend of absorption were compared with reference formulation to prove its bioequivalence in healthy volunteers. Methods: A single-centre, open-label, randomized, two-period, crossover, single dose study under fasting conditions, including at least 7-days washout period, was performed in 30 healthy male and female volunteers. Twenty blood samples were collected in each study period: prior to dosing (0:00) and up to 72:00 hours after dosing and plasma concentrations of irbesartan and hydrochlorothiazide were analysed using preliminary validated methods. Results: The 90% CIs for the geometric mean ratios of test and reference of Cmax and AUC0–t were 89.22% to 98.80% and 100.58% to 115.11%, respectively, for irbesartan and 91.80% to 122.96% and 94.88% to 117.56%, respectively. Thus, the corresponding ratios of Cmax and AUC0-t for irbesartan and hydrochlorothiazide met the predetermined criteria for bioequivalence (90% confidence intervals of the geometric mean ratios of test and reference within the 80.00% - 125.00%). Both the test and reference products demonstrated good tolerability profile in this population, and no serious AEs were observed. Conclusions: Therefore, the test product (Irbesartan/hydrochlorothiazide 300/25 mg film-coated tablets, manufactured by Tchaikapharma High Quality Medicines Inc., Bulgaria) and the reference product (CoAprovel 300/25 mg film-coated tablets, manufactured by Sanofi Clir SNC, France) are considered bioequivalent.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 31 Mar 2023
Bioequivalence and Pharmacokinetics of a Fixed-Dose Combination of Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate in Healthy Thai Volunteers
Research article · 2015
Bioequivalence Study of Two Formulations Containing Irbesartan 300 Mg Tablets in Healthy Colombian Volunteers
Research article · 2011
Single-Dose Bioequivalence of a New Fixed-Dose Combination Tablet Containing Tenofovir Disoproxil Fumarate and Lamivudine
Conference abstract
Bioequivalence of Fixed-Dose Repaglinide/Metformin Combination Tablet and Equivalent Doses of Repaglinide and Metformin Tablet: A Randomized, Single-Dose, Two-Period, Two-Sequence Crossover Study in Healthy Korean Male V
More from this journal
The newest in Health Science Journal.
Editorial · 31 Dec 2025
Energy-Boosting Nutrition: Fueling the Body for Optimal Performance and Vitality
Editorial · 31 Dec 2025
Digestive Balance: Maintaining a Healthy Gut for Optimal Digestion and Well-being
Editorial · 31 Dec 2025
Prebiotics: Exploring the Role of Dietary Components in Supporting Gut Health and Overall Wellness
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalHealth Science Journal
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Katya Uzunova”
- BylineArticles whose byline prints “Andrey Petrov”
- BylineArticles whose byline prints “Emil Gatchev”
- BylineArticles whose byline prints “Velichka Pavlova”
- BylineArticles whose byline prints “Elena Filipova”
- BylineArticles whose byline prints “Cintia Jimenez”
- BylineArticles whose byline prints “Krassimir Kalinov”
- BylineArticles whose byline prints “Toni Vekov”

